Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -39.36 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 12.17 | 12.20 | 10.17 | 8.97 | 7.90 | 13.33 | 16.37 | 18.56 | 102.41 | — | — | — | — |
| — | -8.4% | -37.9% | -51.6% | -92.3% | — | — | — | — | — | — | — | — | |
| P/B Ratio | 18.83 | 27.96 | 21.68 | 16.48 | 9.66 | 10.30 | 8.97 | 5.94 | 7.00 | 6.28 | 11.28 | 121.28 | 40.87 |
| — | +171.6% | +141.7% | +177.5% | +38.0% | +64.0% | -20.5% | -95.1% | -82.9% | -78.6% | -55.5% | +16.4% | +178.8% | |
| P/FCF | — | — | — | 32.64 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Madrigal Pharmaceuticals, Inc.'s operating margin was -29.8% in Q1 2026, down 11.2 pp QoQ and up 28.0 pp YoY. The trailing four-quarter average of -27.6% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin contracted 5.5% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 94.1% | 91.4% | 92.4% | 93.7% | 95.7% | 96.7% | 96.7% | 96.5% | 95.7% | — | — | — | — |
| — | -5.5% | -4.4% | -2.9% | +0.1% | — | — | — | — | — | — | — | — | |
| Operating Margin | -31.3% | -29.8% | -18.6% | -39.7% | -22.2% | -57.8% | -64.8% | -187.1% | -1110.4% | — | — | — | — |
| — | +48.5% | +71.4% | +78.8% | +98.0% | — | — | — | — | — | — | — | — | |
| Net Margin | -30.1% | -30.3% | -18.2% | -39.8% | -19.9% | -53.4% | -57.5% | -172.0% | -1038.2% | — | — | — | — |
| — | +43.2% | +68.3% | +76.9% | +98.1% | — | — | — | — | — | — | — | — |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -42.5% | -16.5% | -9.5% | -17.3% | -6.0% | -10.0% | -7.8% | -13.1% | -17.8% | -23.5% | -52.5% | -157.0% | -67.7% |
| — | -64.7% | -22.9% | -32.0% | +66.2% | +57.4% | +85.2% | +91.7% | +73.7% | +46.9% | +36.4% | +8.9% | -9.7% | |
| ROA | -25.0% | -7.6% | -4.5% | -9.6% | -4.2% | -7.2% | -5.6% | -9.8% | -13.9% | -17.1% | -25.5% | -36.5% | -27.0% |
| — | -5.7% | +20.5% | +2.4% | +69.8% | +58.1% | +78.0% | +73.1% | +48.5% | +22.6% | +22.5% | +15.6% | +16.1% | |
| ROIC | -29.4% | -9.8% | -6.2% | -13.0% | -5.5% | -8.4% | -7.0% | -15.2% | -29.5% | -29.7% | -35.2% | -72.9% | -52.4% |
| — | -17.2% | +10.9% | +14.4% | +81.3% | +71.8% | +80.1% | +79.1% | +43.7% | +90.6% | — | +51.0% | +8.4% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 40.8% YoY to 3.50x, tightening the short-term liquidity position. Debt/Equity has risen for 8 consecutive quarters, indicating increasing financial leverage that investors should watch closely.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.59 | 0.64 | 0.59 | 0.55 | 0.18 | 0.17 | 0.16 | 0.15 | 0.14 | 0.14 | 0.29 | 5.24 | 0.96 |
| — | +279.2% | +271.0% | +261.1% | +29.3% | +21.8% | -45.2% | -97.1% | -85.7% | -75.4% | +14.4% | +12.2% | +61.7% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.01 | 3.50 | 4.01 | 3.44 | 5.11 | 5.91 | 6.10 | 5.98 | 8.72 | 9.39 | 5.38 | 2.36 | 3.02 |
| — | -40.8% | -34.2% | -42.5% | -41.5% | -37.1% | +13.5% | +153.1% | +188.4% | +178.8% | +72.4% | +48.8% | +18.4% | |
| Quick Ratio | 3.77 | 3.16 | 3.77 | 3.26 | 4.78 | 5.58 | 5.90 | 5.93 | 8.67 | 9.39 | 5.38 | 2.36 | 3.02 |
| — | -43.3% | -36.0% | -45.0% | -44.8% | -40.6% | +9.8% | +151.1% | +186.5% | +178.6% | +72.4% | +48.8% | +18.4% | |
| Interest Coverage | -11.92 | -11.86 | -6.06 | -14.33 | -11.95 | -21.21 | -15.98 | -28.07 | -40.57 | -37.44 | -27.25 | -27.18 | -28.58 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Deep dive into MDGL consensus models and risk factors.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MDGL stock.
Madrigal Pharmaceuticals, Inc.'s current P/E is -39.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Madrigal Pharmaceuticals, Inc.'s current operating margin is -31.3%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Madrigal Pharmaceuticals, Inc.'s business trajectory between earnings reports.